Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBIT (2016 - 2025)

Coherus Oncology's EBIT history spans 13 years, with the latest figure at -$45.9 million for Q4 2025.

  • For Q4 2025, EBIT fell 1.09% year-over-year to -$45.9 million; the TTM value through Dec 2025 reached -$181.1 million, up 9.28%, while the annual FY2025 figure was -$181.1 million, 9.28% up from the prior year.
  • EBIT for Q4 2025 was -$45.9 million at Coherus Oncology, down from -$44.3 million in the prior quarter.
  • Across five years, EBIT topped out at -$24.2 million in Q2 2021 and bottomed at -$167.4 million in Q1 2021.
  • The 5-year median for EBIT is -$45.5 million (2025), against an average of -$55.2 million.
  • The largest annual shift saw EBIT plummeted 509.51% in 2021 before it skyrocketed 60.22% in 2023.
  • A 5-year view of EBIT shows it stood at -$39.5 million in 2021, then tumbled by 30.21% to -$51.5 million in 2022, then crashed by 33.81% to -$68.9 million in 2023, then surged by 34.14% to -$45.4 million in 2024, then decreased by 1.09% to -$45.9 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EBIT are -$45.9 million (Q4 2025), -$44.3 million (Q3 2025), and -$45.5 million (Q2 2025).